Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors
Development collaboration integrates Sartorius Stedim Biotech’s BIOSTAT® STR bioreactors and Repligen’s XCell™ ATF cell retention control technology Customers to benefit from simplified, scalable solutions for intensified cell culture GÖTTINGEN, Germany and WALTHAM, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) - Sartorius Stedim Biotech (SSB) (Euronext: DIM), a leading international supplier for the biopharmaceutical industry, and Repligen Corporation (NASDAQ:RGEN), a global life sciences company focused on bioprocessing technologies, have entered into a collaboration agreement to integrate Repligen’s XCell™ ATF cell retention control technology into SSB’s BIOSTAT ® STR large-scale single-use bioreactors to create novel perfusion-enabled bioreactors. As a result of this collaboration, end users will stand to benefit from a single control system for 50 L to 2,000 L bioreactors used in perfusion cell culture applications. This single interface is designed to control cell growth, fluid